The Danish biotechnology company and partner AbbVie said a drug combination to treat lymphoma met the primary goal in a ...

Genmab A/S – ADR GMAB on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial. The trial evaluated the ...

Despite a recent failure as a second-line monotherapy in diffuse B-cell lymphoma (DLBLC), a positive phase 3 combination ...

Company AnnouncementTopline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated ...

Genmab ( (GMAB)) has provided an update. Genmab A/S, an international biotechnology company specializing in next-generation antibody medicines for cancer, develops bispecific antibodies, antibody–drug ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Genmab A/S (NASDAQ:GMAB) is one of the 15 large cap stocks under $30 with huge upside potential. As of the March 23 closing, consensus sentiment for Genmab A/S (NASDAQ:GMAB) remained strongly bullish.

The latest price target for Genmab (NASDAQ:GMAB) was reported by HC Wainwright & Co. on June 23, 2026. The analyst firm set a price target for $38.00 expecting GMAB to rise to within 12 months (a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As the oncology landscape continues to evolve, companies are increasingly evaluated on their ability to translate scientific expertise into sustained patient impact. For Genmab, long recognized for ...

Genmab A/S GMAB and AbbVie Inc ABBV have announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody CD3xCD20), an ...